Results 251 to 260 of about 51,741 (305)

T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. [PDF]

mSphere
Wangteeraprasert A, Pongcharoen S, Ngoenkam J, Makanut S.   +3 more
europepmc   +1 more source

Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barré Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine. [PDF]

Cureus
Kumar C, Akhileshwar, Kumar Neeraj R, Hameed S, Husain N, Roy SS, Mohan L, Anantsaznam.   +7 more
europepmc   +1 more source

Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines. [PDF]

Nat Commun
Chen W, Tompkins KR, Windsor IW, Martinez LT, Ramos M, Li W, Shrivastava S, Rajput S, Chang JS, Sahasrabudhe P, Fennell KF, McLellan TJ, West GM, Dizon KP, Yam A, Mitra S, Saha S, Sharaf D, McKeen AP, Cadima CI, Muik A, Swanson W, Munoz Moreno R, Mendoza Daroca P, Sahin U, Anderson AS, Wu H, Swanson KA, Modjarrad K.   +28 more
europepmc   +1 more source

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Nature, 2021
Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, S. Weaver, K. Swanson, Hui Cai, Mark Cutler, David Cooper, A. Muik, K. Jansen, U. Şahin, Xuping Xie, P. Dormitzer, P. Shi   +14 more
semanticscholar   +1 more source

Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial. [PDF]

Vaccines (Basel)
Putri ND, Zhafira AS, Wicaksana P, Satari HI, Fadlyana E, Safitri V, Nurlailah N, Putri ES, Putri N, Iriyani DS, Ulina YS, Aprilia F, Pratama E, Nethalia I, Yustisiana R, Aini EQ, Fajarani R, Susilo A, Karyanti MR, Prayitno A, Sukandar H, Watts E, Mazarakis N, Multihartina P, Setiawaty V, Pangesti KNA, Indrati AR, Sundoro J, Handayani DO, Kartasasmita CB, Hadinegoro SR, Mulholland K.   +31 more
europepmc   +1 more source

Quantity of Work Days Lost Due To Side Effects Among Health Care Workers Vaccinated with Bnt162b2 and Chadox1

Christian Scheer, Sven‐Olaf Kuhn, Marén Fricke, Lars Lars G. Eckerle, Astrid Radau, Lars Kaderali, Matthias Gründling, Marcus Vollmer   +7 more
openalex   +1 more source

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children. [PDF]

Open Forum Infect Dis
Vogler I, Renken S, Hilker R, Lui BG, Finlayson A, Gurtman A, Sabharwal C, Kitchin N, Lockhart S, Gruber WC, Jansen KU, Swanson KA, Türeci Ö, Şahin U.   +13 more
europepmc   +1 more source

The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old

Charlie McLeod, Michael Dymock, Katie L. Flanagan, Magdalena Plebanski, Helen Marshall, Marie J. Estcourt, Ushma Wadia, Christian Tjiam, Christopher C. Blyth, Kanta Subbarao, Francesca L. Mordant, Suellen Nicholson, Natalie Cain, Rianne Brizuela, Saul N. Faust, Ruth B. Thornton, Anne McKenzie, Julie Marsh, Tom Snelling, Peter Richmond   +19 more
openalex   +1 more source

Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids. [PDF]

Nat Biomed Eng
Zhao Y, Li R, Liu P, Wang J, Cui Y, Ma Y, Cao Z, Cui M, Luozhong S, Wagner E, Laflin A, Ding Y, Hu Y, Tian Z, Tang C, Cai S, Young H, Liu D, Gu W, Bailey S, Jiang S.   +20 more
europepmc   +1 more source

A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity. [PDF]

Front Immunol
Etna MP, Fuoco C, Severa M, Ricci D, Sinigaglia A, Lucca C, Cairo G, Bottazzi B, Garlanda C, Palamara AT, Barzon L, Gargioli C, Coccia EM.   +12 more
europepmc   +1 more source